News

All news

CSR Events General PERSONAL CARE Press release Products & Technologies Protéus

CELLforCURE launches a process to find a buyer for its Les Ulis site

CELLforCURE, a subsidiary of the SEQENS Group, has informed its employee representatives of its decision to look for a potential buyer for its site in Les Ulis (Essonne). CELLforCURE specializes in the development and the contract manufacturing of Cell & Gene therapies.

SEQENS has announced it has reached an agreement in principle on a comprehensive financial restructuring

SEQENS to launch PeptiCode™ HP-9: the first European biotech Hexapeptide-9

Sale of our Limoges Botanical Actives and In Vitro Diagnostics activities to Solabia

NEO Solvents: 5 Criteria for a more Sustainable Chemistry

Formulating Differently: Biobased Diols, the Key to Ecofriendly & Effective Cosmetics

SEQENS new antiwear additive ROSCAN® 6253NV is registered on the LUSC list.

Pharma

Brenntag and SEQENS partner for the commercialization of non-GMP pharmaceutical intermediates in Europe

At the Roussillon site, the development of the future paracetamol production unit is progressing steadily.

SEQENS: Exemplary Ecovadis scores in 2025

CSR

SEQENS: a benchmark in CSR recognized by Ecovadis

CELLforCURE : CELL 2025 UK, Advanced Therapies US, ATMP Sweden and More, let’s meet !

BBG Advanced Therapies and CELLforCURE partner to provide transatlantic manufacturing solutions for ATMPs

1 2 3 … 7

Contact